Chugai Pharmaceutical Co.... (CHGCF)

PNK: CHGCF · Real-Time Price · USD

57.58

1.19 (2.11%)

At close: May 02, 2025, 1:15 PM

Chugai Pharmaceutical Income Statement

Financials in JPY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Revenue	1,170.6B	1,111.4B	1,259.9B	999.76B	786.95B	686.18B	579.79B	534.2B	491.78B
Cost of Revenue	339.41B	413.31B	476.25B	338.15B	273.46B	266.07B	262.85B	254.17B	247.94B
Gross Profit	831.2B	698.06B	783.7B	661.61B	513.48B	420.11B	316.94B	280.03B	243.84B
Operating Income	542B	439.17B	533.31B	421.9B	301.23B	210.6B	124.32B	98.93B	76.88B
Interest Income	5M	4.65B	182M	166M	121M	109M	n/a	n/a	1.11B
Pretax Income	543.03B	443.82B	531.17B	419.38B	298.19B	207.89B	121.45B	97.03B	74.45B
Net Income	387.32B	325.47B	374.43B	303B	214.73B	157.56B	92.49B	72.71B	53.59B
Selling & General & Admin	110.1B	112.58B	100.76B	102.42B	94.4B	101.57B	93.42B	88.15B	81.94B
Research & Development	181.44B	174.87B	149.63B	137.3B	117.85B	107.94B	99.2B	92.95B	85.01B
Other Expenses	-2.34B	-28.56B	-2.13B	-2.54B	-1.5B	-3.12B	-3.21B	-1.71B	-3.46B
Operating Expenses	289.2B	258.89B	250.39B	239.72B	212.25B	209.52B	192.62B	181.09B	166.95B
Interest Expense	-1.03B	n/a	61M	48M	62M	125M	111M	110M	86M
Selling & Marketing Expenses	110.1B	112.58B	77.15B	76.59B	72.58B	77.18B	73.71B	72.8B	69.77B
Cost & Expenses	628.61B	672.19B	726.64B	577.86B	485.72B	475.59B	455.46B	435.26B	414.9B
Income Tax Expense	155.72B	118.35B	156.74B	116.39B	83.45B	50.33B	28.37B	23.49B	20.08B
Shares Outstanding (Basic)	1.65B	1.65B	1.64B	1.64B	1.64B	1.64B	1.64B	1.64B	1.64B
Shares Outstanding (Diluted)	1.65B	1.65B	1.65B	1.65B	1.65B	1.64B	1.64B	1.64B	1.64B
EPS (Basic)	235.35	197.80	227.64	184.29	130.66	95.95	56.32	44.35	32.71
EPS (Diluted)	235.36	197.80	227.57	184.17	130.53	95.81	56.24	44.28	32.66
EBITDA	542B	443.85B	531.23B	419.43B	298.25B	208.02B	121.56B	115.27B	93.25B
EBIT	542B	443.85B	531.23B	419.43B	298.25B	208.02B	121.56B	97.14B	74.53B
Depreciation & Amortization	n/a	4.67B	31.43B	30.87B	30.48B	26.4B	16.58B	16.33B	16.37B